Article

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma

2023-11-20

Abstract excerpt

<title>Abstract</title> <p>Immune checkpoint blockade is a highly successful anti-cancer immunotherapy. Both CTLA4 and PD1 checkpoint blockers are clinically available for melanoma treatment, with anti-PD1 therapy reaching response rates of 35-40%. These responses, which are mediated via neoantigen presentation by the polymorphic MHC complex, are hard to predict and the tumor mutation burden is currently the best...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0401d9f5-1b57-5e17-82e8-db470169eca8
DOI: 10.21203/rs.3.rs-3224114/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaDOI 10.21203/rs.3.rs-3224114/v1Read

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read

LncRNA antigens- a novel resource to improve immunotherapy efficacy predictions in MelanomaSemantic proximity Read

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Semantic proximity Read

LncRNA antigens - a novel resource to improve immunotherapy efficacy predictions in melanomaSemantic proximity Read

HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.Semantic proximity Read

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance MechanismsSemantic proximity Read

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read

MHC-I genotype and tumor mutational burden predict response to immunotherapy.Semantic proximity Read

Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockadeSemantic proximity Read

Association between cancer risk and HLA genotype can be explained by anti-tumor immunitySemantic proximity Read

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisSemantic proximity Read

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read